Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a devastating prognosis. The pathogenesis is not clear but involves repetitive lung injury with aberrant inflammatory response. In the last two decades, multiple therapeutic drug trials have been completed failing to identify an effective treatment for this disease. Lung transplant has been the only effective option for patients with IPF. Over the last 5 years, two agents have demonstrated significant slowing in IPF progression. Pirfenidone and nintedanibe are new drugs that showed promising results in IPF treatment. The drugs were approved in Japan and Europe in 2008 and 2011 respectively. The U.S Food and Drugs Administrations approved these medications recently in October 2014. Published clinical trials are reviewed with these two agents and the risks and benefits of therapy for IPF are discussed. Information is provided in this review to assist physicians in the decision making process related to starting one of these agents in patients with IPF.
Keywords: Idiopathic pulmonary fibrosis, interstitial lung diseases, new treatments, nintedanib, pathogenesis, pirfenidoen.
Current Drug Therapy
Title:New Approved Medications for Idiopathic Pulmonary Fibrosis
Volume: 10 Issue: 2
Author(s): Shehabaldin Alqalyoobi and Gary A. Salzman
Affiliation:
Keywords: Idiopathic pulmonary fibrosis, interstitial lung diseases, new treatments, nintedanib, pathogenesis, pirfenidoen.
Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a devastating prognosis. The pathogenesis is not clear but involves repetitive lung injury with aberrant inflammatory response. In the last two decades, multiple therapeutic drug trials have been completed failing to identify an effective treatment for this disease. Lung transplant has been the only effective option for patients with IPF. Over the last 5 years, two agents have demonstrated significant slowing in IPF progression. Pirfenidone and nintedanibe are new drugs that showed promising results in IPF treatment. The drugs were approved in Japan and Europe in 2008 and 2011 respectively. The U.S Food and Drugs Administrations approved these medications recently in October 2014. Published clinical trials are reviewed with these two agents and the risks and benefits of therapy for IPF are discussed. Information is provided in this review to assist physicians in the decision making process related to starting one of these agents in patients with IPF.
Export Options
About this article
Cite this article as:
Alqalyoobi Shehabaldin and Salzman A. Gary, New Approved Medications for Idiopathic Pulmonary Fibrosis, Current Drug Therapy 2015; 10 (2) . https://dx.doi.org/10.2174/157488551002151222155158
DOI https://dx.doi.org/10.2174/157488551002151222155158 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic
Steatosis: A Prospective Observational Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Renal Cell Cancer and Positron Emission Tomography- an Evolving Diagnostic and Therapeutic Relationship
Current Medical Imaging Thalidomide Analogues as Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Interactions between Transporters and Herbal Medicines/Drugs: A Focus on Hepatoprotective Compounds
Current Drug Metabolism Manipulation of Dendritic Cells for Tumor Immunity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Retracted: Effects of Vitamin K2 on Osteoporosis
Current Pharmaceutical Design Anticancer Drug Discovery from the Marine Environment
Recent Patents on Anti-Cancer Drug Discovery Angiogenesis and the Heart
Recent Patents on Cardiovascular Drug Discovery Role of NF-κB in the Regulation of Cytochrome P450 Enzymes
Current Drug Metabolism Metallothioneins, Ageing and Cellular Senescence: A Future Therapeutic Target
Current Pharmaceutical Design The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Current Cancer Drug Targets Identification and Induction of Cytochrome P450s Involved in the Metabolism of Flavone-8-Acetic Acid in Mice
Drug Metabolism Letters Matrix Metalloproteinase Inhibitors as Prospective Agents for the Prevention and Treatment of Cardiovascular and Neoplastic Diseases
Current Topics in Medicinal Chemistry Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Identification and Targeting of Tumor Escape Mechanisms: A New Hope for Cancer Therapy?
Current Pharmaceutical Design Gastrointestinal Stromal Tumors: A Paradigm for Therapeutic Options in Solid Organ Tumors
Mini-Reviews in Medicinal Chemistry Natural History of the Nihon Rat Model of BHD
Current Molecular Medicine Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry The HOX Gene Network as a Potential Target for Cancer Therapy
Current Cancer Therapy Reviews